# Tuberculosis Diagnostics Market

> Tuberculosis Diagnostics Market Research Report: Size, Share, Trend Analysis By Disease Severity (Low Severity, Moderate Severity, High Severity), By Technology (Molecular Diagnostics, Microscopy-Based Diagnostics, Immunodiagnostics, Culture-Based Diagnostics), By Sample Type (Sputum, Blood, Urine, Tissue) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.16%
- **2024:** $ 1.76 Billion
- **2025:** $ 1.85 Billion
- **2035:** $ 3.06 Billion
- **Key Players:** Companies such as Roche (CH), Abbott (US), Thermo Fisher Scientific (US), BD (US), Hologic (US), Cepheid (US), Mylan (IN), Siemens Healthineers (DE), Quotient Limited (GB) are some of the major participants in the global market.

**Report ID:** MRFR/MED/9845-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/tuberculosis-diagnostics-market-11365

---

## Market Summary

## **Tuberculosis Diagnostics Market Overview**

As per MRFR analysis, the Tuberculosis Diagnostics Market Size was estimated at 1.76 (USD Billion) in 2024. The Tuberculosis Diagnostics Market Industry is expected to grow from 1.85 (USD Billion) in 2025 to 2.9 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.16% during the forecast period (2025 - 2034).

### **Key Tuberculosis Diagnostics Market Trends Highlighted**

Of note, the rise in the prevalence of tuberculosis (TB) cases, increasing demand for rapid and accurate diagnostic tests, and advancements in molecular and genetic technologies are fueling market expansion. Moreover, growing awareness about TB and its diagnosis, coupled with favorable government initiatives and collaborative efforts among stakeholders, offer significant growth opportunities. Additionally, the recent trend towards point-of-care testing and the development of novel TB diagnostics, such as those based on artificial intelligence and biosensors, are expected to shape the market in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Tuberculosis Diagnostics Market Drivers**

### **Increasing Prevalence of Tuberculosis**

Tuberculosis (TB) is a bacterial infection that primarily affects the lungs. It is a major public health concern, with an estimated 10 million new cases and 1.5 million deaths worldwide each year. The increasing prevalence of TB is a significant driver of the growth of the Tuberculosis Diagnostics Market. Factors contributing to the rise in TB cases include population growth, urbanization, poverty, and the emergence of drug-resistant strains. As the number of TB cases increases, the demand for accurate and timely diagnostics is expected to surge, driving market growth.

### **Technological Advancements in Diagnostics**

The development of modern methods of diagnostics is one of the primary factors that have contributed to the more accurate and faster detection of TB, as well as enhanced diagnostic accessibility. In particular, the appearance of[molecular diagnostics](../../../reports/molecular-diagnostics-market-1171) and, specifically, polymerase chain reaction tests and GeneXpert MTB/RIF assays, had tremendous significance for the field. Such tests can be carried out much faster and can efficiently detect the existence of Rica or RNAr and respectively, the presence of the bacteria M. Tuberculosis causes the disease, as well as provides information about drug resistance.

The increasing popularity and availability of these technologies are expected to be considerable drivers of the growth of the Tuberculosis Diagnostics Market.

### **Rising Demand for Point-of-Care Diagnostics**

The growing need for point-of-care (POC) diagnostics is another key driver of the Tuberculosis Diagnostics Market. POC tests are designed to provide rapid and accurate results in settings where traditional laboratory testing is not feasible. POC tests for TB are particularly valuable in resource-limited areas, where access to healthcare facilities is limited. The development of new POC technologies, such as lateral flow assays and microfluidics-based devices, is expected to further drive the adoption of POC TB diagnostics, contributing to the overall growth of the market.

## **Tuberculosis Diagnostics Market Segment Insights**

### **Tuberculosis Diagnostics Market Disease Severity Insights**

The Tuberculosis Diagnostics Market is segmented based on disease severity into low severity, moderate severity and high severity. The high-severity segment is expected to hold the largest market share and grow at the highest CAGR during the forecast period. This growth is attributed to the increasing prevalence of drug-resistant tuberculosis and the need for accurate and rapid tuberculosis diagnostics. The low-severity segment is expected to hold a considerable market share because of the high prevalence of latent tuberculosis infection. Latent TB infection is a condition in which people are infected with the TB bacteria but do not have active disease.

The moderate severity segment is also expected to hold a significant market share because of the increasing awareness about TB and its effective treatment.

Thus, the market for TB diagnostics is expected to grow significantly in the future, as an increasing number of people are being affected by TB, also because of the emergence of drug-resistant strains, which require accurate and timely TB diagnostics. In order to capitalize on the demand, the key market players are developing innovative diagnostics technologies. Some of the emerging TB diagnostics technologies are the molecular tests and the rapid diagnostic tests. The molecular tests can easily identify the disease with high levels of accuracy, specificity and sensitivity at any stage of the disease.

The rapid diagnostic tests can provide results within 2 h, which is not feasible with a conventional culture test.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Tuberculosis Diagnostics Market Technology Insights**

The Tuberculosis Diagnostics Market is segmented by Technology into Molecular Diagnostics, Microscopy-Based Diagnostics, Immunodiagnostics and Culture-Based Diagnostics. The Molecular Diagnostics segment is expected to account for the largest share of the market in 2023, owing to the increasing adoption of molecular diagnostic tests such as PCR and GeneXpert. The Microscopy-Based Diagnostics segment is expected to be the second-largest segment due to its cost-effectiveness and wide availability. The Immunodiagnostics segment is expected to witness significant growth in the coming years, owing to the increasing availability of rapid diagnostic tests.

The Culture-Based Diagnostics segment is expected to account for a smaller share of the market due to its longer turnaround time and lower sensitivity.

### **Tuberculosis Diagnostics Market Sample Type Insights**

The Tuberculosis Diagnostics Market is segmented into sputum, blood, urine and tissue sample types. Among these, the sputum segment held the largest market share in 2023, accounting for over 50% of the total revenue. This dominance is attributed to the ease of sputum collection and its high sensitivity in detecting TB bacteria. The blood sample type segment is expected to witness the fastest growth during the forecast period, owing to the increasing adoption of molecular diagnostics, such as PCR and LAMP assays, which offer rapid and accurate detection of TB.

The urine sample type segment is also expected to grow steadily, driven by the development of non-invasive diagnostic tests that can detect TB bacteria in urine samples. The tissue sample type segment holds a relatively small market share, but it is gaining importance due to its ability to provide a definitive diagnosis of TB, especially in cases of extrapulmonary infections.

### **Tuberculosis Diagnostics Market Regional Insights**

The regiol segmentation of the Tuberculosis Diagnostics Market offers valuable insights into the market's dynamics across different regions. North America is expected to hold a significant share of the market, driven by factors such as well-established healthcare infrastructure, high prevalence of tuberculosis and government initiatives to combat the disease. Europe is another key region in the market, with a mature healthcare system and a focus on early diagnosis and treatment of tuberculosis.

The Asia-Pacific (APAC) region is expected to witness robust growth in the coming years, primarily due to the increasing prevalence of tuberculosis, rising healthcare expenditure and growing awareness about the disease. South America and the Middle East and Africa (MEA) regions are also expected to contribute to the market growth, albeit at a slower pace compared to other regions. The MEA region, in particular, faces challenges related to access to healthcare services and limited infrastructure, which may hinder the growth of the tuberculosis diagnostics market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Tuberculosis Diagnostics Market Key Players And Competitive Insights**

The Tuberculosis Diagnostics Market is generally carried out under a few major players. More specifically, the leading Tuberculosis Diagnostics Market players are constantly investing in research and development, in order to introduce innovative solutions and products to the market. The development of the Tuberculosis Diagnostics Market is driven by a range of factors, including increased prevalence of the disease, increased demand for fast and accurate diagnostics, and growth in global healthcare spending. The Tuberculosis Diagnostics Market Competitive Landscape is expected to intensify due to the entry of new players, as well as the expansion of the existing players.

Hologic Inc. is a leading company that provides Tuberculosis Diagnostics Market solutions. The company offers an extensive product line, which includes molecular diagnostics, rapid diagnostics, as well as culture-based diagnostics. Hologic Inc. has a well-developed distribution strategy and a strong international presence. The company is capitalizing on customer demand for high-quality diagnostics and customer-oriented strategies. At the same time, Hologic Inc. is well-positioned in the Tuberculosis Diagnostics Market due to its focus on product and solution innovation.

Becton, Dickinson and Company is another superb player in the Tuberculosis Diagnostics Market. For the purposes of this discussion, it is pertinent to note that BD’s product line spans the range of automated molecular diagnostics, rapid diagnostics, and culture-based diagnostics. Now, the company has a well-developed international presence and is deeply rooted in both developed and developing markets. At the same time, BD’s commitment to research and development is driving the success of a broad range of novel diagnostics technologies.

### **Key Companies in the Tuberculosis Diagnostics Market Include**

- [Cepheid](https://www.cepheid.com/en-US/tests/tb-emerging-infectious-diseases/xpert-mtb-rif.html)
- Alere
- Danaher
- Hologic
- BD
- [BioRad Laboratories](https://www.bio-rad-antibodies.com/polyclonal/bacterial-mycobacterium-tuberculosis-antibody-obt0947.html)
- Becton, Dickinson and Company
- Hain Lifescience
- Roche
- Sanofi
- Abbott
- Qiagen
- Sysmex
- Seegene

## **Tuberculosis Diagnostics Market Industry Developments**

The Tuberculosis Diagnostics Market is anticipated to reach a valuation of USD 2.5 billion by 2032, expanding at a CAGR of 5.16% from 2024 to 2032. The market growth is attributed to the increasing prevalence of tuberculosis, technological advancements in diagnostic techniques, and the rising demand for rapid and accurate diagnostic tests.

Key developments in the market include the approval of novel diagnostic tests, such as molecular assays and rapid diagnostic tests, which offer improved sensitivity and specificity. Additionally, the increasing focus on early detection and the growing awareness of tuberculosis control programs are expected to drive market expansion.

## **Tuberculosis Diagnostics Market Segmentation Insights**

### **Tuberculosis Diagnostics Market Disease Severity Outlook**

- Low Severity
- Moderate Severity
- High Severity

### **Tuberculosis Diagnostics Market Technology Outlook**

- Molecular Diagnostics
- Microscopy-Based Diagnostics
- Immunodiagnostics
- Culture-Based Diagnostics

### **Tuberculosis Diagnostics Market Sample Type Outlook**

- Sputum
- Blood
- Urine
- Tissue

### **Tuberculosis Diagnostics Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Incidence of Tuberculosis

The increasing incidence of tuberculosis (TB) worldwide is a primary driver for the Tuberculosis Diagnostics Market. According to the World Health Organization, there were approximately 10 million new TB cases reported in 2020, highlighting a persistent public health challenge. This rising trend necessitates the development and deployment of effective diagnostic tools to identify and treat TB cases promptly.
 
The demand for rapid and accurate diagnostic solutions is expected to grow, as healthcare systems strive to manage and control TB outbreaks. Furthermore, the emergence of drug-resistant strains of TB complicates treatment protocols, thereby amplifying the need for advanced diagnostic technologies. As a result, stakeholders in the market are likely to invest in innovative solutions that can enhance detection rates and improve patient outcomes.

### Increased Awareness and Education

Increased awareness and education regarding tuberculosis are pivotal in driving the Tuberculosis Diagnostics Market. Public health campaigns aimed at educating communities about TB symptoms, transmission, and the importance of early diagnosis have led to a rise in testing and screening initiatives. As individuals become more informed about the disease, they are more likely to seek diagnostic services, thereby increasing demand for TB testing.
 
Furthermore, healthcare professionals are being trained to recognize TB symptoms and recommend appropriate diagnostic tests, which enhances the overall detection rate. This heightened awareness not only contributes to early diagnosis but also helps in reducing stigma associated with TB, encouraging more individuals to seek help. Consequently, the market is likely to benefit from this growing emphasis on education and awareness.

### Government Initiatives and Policies

Government initiatives and policies aimed at combating tuberculosis are significantly influencing the Tuberculosis Diagnostics Market. Many countries have implemented national TB control programs that prioritize early diagnosis and treatment. For instance, funding allocations for TB diagnostics have increased, with governments recognizing the importance of timely detection in reducing transmission rates.
 
The WHO's End TB Strategy emphasizes the need for improved diagnostic capabilities, which has led to the adoption of new technologies such as molecular diagnostics and rapid tests. These initiatives not only enhance the availability of diagnostic tools but also encourage public-private partnerships to foster innovation in the market. As governments continue to prioritize TB control, the market is expected to witness sustained growth driven by supportive policies and funding.

### Emergence of Drug-Resistant Tuberculosis

The emergence of drug-resistant tuberculosis (DR-TB) is a critical factor influencing the Tuberculosis Diagnostics Market. As the prevalence of DR-TB rises, there is an urgent need for advanced diagnostic tools that can accurately identify resistant strains of the bacteria. The WHO estimates that approximately 3.3% of new TB cases and 18% of previously treated cases are multidrug-resistant, necessitating the development of specialized diagnostic tests.
 
These tests are essential for guiding appropriate treatment regimens and preventing further transmission of resistant strains. The increasing complexity of TB management due to drug resistance is likely to drive innovation in the diagnostics sector, as stakeholders seek to develop solutions that can effectively address this challenge. Thus, the market is poised for growth as it adapts to the evolving landscape of TB treatment and diagnosis.

### Technological Innovations in TB Diagnostics

Technological innovations are reshaping the Tuberculosis Diagnostics Market, offering new avenues for enhanced detection and management of TB. Advances in molecular diagnostics, such as polymerase chain reaction (PCR) and [next-generation sequencing](https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354), have significantly improved the speed and accuracy of TB diagnosis. These technologies enable the identification of TB pathogens in a matter of hours, which is crucial for timely treatment initiation.
 
Additionally, the integration of artificial intelligence and machine learning in diagnostic tools is expected to further streamline the diagnostic process, allowing for better patient stratification and management. The market for TB diagnostics is projected to grow as healthcare providers increasingly adopt these innovative technologies to improve patient care and outcomes. The ongoing research and development in this field suggest a promising future for the market.

## Future Outlook

The Tuberculosis Diagnostics Market size is projected to reach USD 3.055 Billion by 2035, growing at a CAGR of 5.1%, driven by technological advancements, increasing prevalence, and enhanced healthcare initiatives.

**New opportunities:**

- Development of rapid molecular testing kits for remote areas. Integration of AI-driven analytics in diagnostic platforms. Expansion of [telemedicine](https://www.marketresearchfuture.com/reports/telemedicine-market-2216) services for remote patient monitoring.

By 2035, the market is expected to be robust, driven by innovation and increased accessibility.

## Segment Insights

### By Disease Severity: Moderate Severity (Largest) vs. High Severity (Fastest-Growing)

The disease severity segment is crucial for understanding patient needs and treatment outcomes. The distribution is such that the Moderate Severity category holds the largest Tuberculosis Diagnostics Market share, primarily due to its prevalence in untreated or late-diagnosed populations. High Severity is gaining traction as rising awareness and advancements in diagnostic technologies drive demand for more effective testing methods among patients with severe symptoms, thereby expanding its market presence.

Moderate Severity (Dominant) vs. High Severity (Emerging)

Moderate Severity cases represent a significant portion of the Tuberculosis Diagnostics Market, characterized by a consistent demand for effective diagnostic tests. These patients often exhibit noticeable symptoms that trigger earlier testing and treatment interventions, thus fostering stability within this segment. On the other hand, High Severity cases are on the rise, partly propelled by increased public health efforts and funding aimed at addressing severe tuberculosis outbreaks. As technologies evolve and the healthcare infrastructure improves, the market for diagnostics in high-severity cases is expected to flourish, attracting investments and innovation to cater to this emerging segment.

### By Technology: Molecular Diagnostics (Largest) vs. Microscopy-Based Diagnostics (Fastest-Growing)

The market is significantly led by Molecular Diagnostics, which has gained a substantial share due to its high sensitivity and specificity in detecting Mycobacterium tuberculosis. Following closely is Microscopy-Based Diagnostics, which, while in the shadow of molecular technologies, continues to hold a vital role due to its cost-effectiveness and relative accessibility in low-resource settings. As healthcare systems invest in upgrading diagnostic technologies, these segment values exhibit a diverging market presence, with [Molecular Diagnostics](https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171) notably dominating overall Tuberculosis Diagnostics Market share. Growth trends in the market indicate a steady increase in the adoption of advanced molecular techniques, driven by the need for rapid and accurate diagnoses. Meanwhile, Microscopy-Based Diagnostics is witnessing a resurgence as newer microscopy technologies enter the market, enabling faster detection times and enhanced accuracy, thus appealing to regions with limited resources. The emphasis on early detection and accurate results in TB management supports the overall market's expansion, reflecting a shift towards more efficient diagnostic approaches.

Molecular Diagnostics: Dominant vs. Culture-Based Diagnostics: Emerging

Molecular Diagnostics stands as the dominant force within the market, primarily characterized by its ability to deliver rapid and precise results through techniques such as [PCR](https://www.marketresearchfuture.com/reports/polymerase-chain-reaction-market-19212) and NGS. This segment benefits from continuous innovation, with ongoing research enhancing the capabilities of molecular methods, thus making them preferable for detecting TB in both symptomatic and asymptomatic populations. In contrast, Culture-Based Diagnostics, although considered an emerging segment, plays a crucial role in confirming TB cases, especially for drug susceptibility testing. It tends to be slower and less sensitive compared to molecular methods, but remains integral to comprehensive TB management strategies in settings where laboratory infrastructure supports prolonged testing processes. Together, these segments illustrate the dynamic interplay between advanced diagnostics and traditional methods.

### By Sample Type: Sputum (Largest) vs. Blood (Fastest-Growing)

In the market, the sample type segment is primarily characterized by sputum, blood, urine, and tissue samples. Sputum remains the dominant choice for tuberculosis diagnosis, capturing the largest share due to its effectiveness in identifying Mycobacterium tuberculosis. Blood and urine samples are gaining traction because they offer less invasive testing methods, providing a significant opportunity for growth as awareness of tuberculosis increases globally. Whereas tissue samples are less commonly used, they play a critical role in a more precise diagnosis when needed. The growth trends in sample types highlight a shift towards less invasive and rapid diagnostic methods. Blood sampling, being noted as the fastest-growing segment, benefits from technological advancements in serology and molecular testing. Factors driving this growth include increasing awareness about tuberculosis, a rise in the number of tuberculosis cases, and the need for quicker, more efficient diagnostic processes. This reflects an industry trend towards patient-centered care in tuberculosis diagnosis, catering to diverse patient needs and improving overall access to diagnosis services.

Sputum (Dominant) vs. Tissue (Emerging)

Sputum remains the dominant sample type in the Tuberculosis Diagnostics Market due to its established reliability and accuracy for diagnosing tuberculosis. Sputum tests are instrumental in detecting the presence of the bacterium early, which is vital for effective treatment outcomes. As the gold standard for TB diagnosis, they are widely used in clinical settings. On the other hand, tissue sampling is considered an emerging option important for distinguishing between active infection and latent tuberculosis. It is primarily employed in complex cases where a precise diagnosis is critical. While still less common, advancements in biopsy techniques and the growing demand for accurate diagnostic methods are paving the way for tissue samples to become more recognized in tuberculosis diagnostics.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America leads in the Tuberculosis Diagnostics Market Size, accounting for over 39.86% of the global revenue in 2024. The region benefits from advanced healthcare infrastructure, high R&D investments, and stringent regulatory frameworks that promote innovation. The increasing prevalence of tuberculosis and the demand for rapid diagnostic solutions are key growth drivers.

Regulatory support, including initiatives from the CDC and FDA, further catalyzes market expansion. The United States is the dominant player in this region, with significant contributions from companies like Abbott, Thermo Fisher Scientific, and Cepheid.

The competitive landscape is characterized by a focus on technological advancements and partnerships aimed at enhancing diagnostic accuracy. Canada also plays a vital role, with a growing emphasis on public health initiatives to combat tuberculosis, thereby supporting the overall market growth.

### Europe : Regulatory Support and Innovation

Europe Tuberculosis Diagnostics Market size was valued at USD 0.53 Billion in 2024, making it the second-largest regional market with a 30% share. The region is characterized by robust healthcare systems and a strong emphasis on public health policies aimed at tuberculosis control.

Regulatory bodies like the European Medicines Agency (EMA) are actively involved in streamlining the approval processes for innovative diagnostic tools, which is expected to drive market growth in the coming years. Leading countries in this region include Germany, France, and the UK, where significant investments in healthcare technology are being made.

Key players such as Roche and Siemens Healthineers are at the forefront, focusing on developing advanced diagnostic solutions. The competitive landscape is marked by collaborations between public health organizations and private companies, enhancing the availability and accessibility of tuberculosis diagnostics across Europe.

### Asia-Pacific : Rapid Growth and Demand

Asia-Pacific is witnessing rapid growth in the tuberculosis diagnostics market, holding approximately 25% of the global share. The region's high burden of tuberculosis, coupled with increasing healthcare investments, drives demand for effective diagnostic solutions. Government initiatives aimed at enhancing tuberculosis control and the introduction of new technologies are significant catalysts for market expansion.

Countries like India and China are leading the charge, with substantial public health programs in place. India is a key player in this market, with a growing number of local manufacturers and collaborations with international firms. The competitive landscape is evolving, with companies like Mylan and Hologic making strides in developing affordable diagnostic tools. The region's diverse healthcare needs and varying levels of infrastructure present both challenges and opportunities for market players, fostering innovation and adaptation in tuberculosis diagnostics.

### Middle East and Africa : Emerging Markets and Challenges

The Middle East and Africa region is increasingly focusing on tuberculosis diagnostics, holding about 5% of the global market share. The high prevalence of tuberculosis, particularly in sub-Saharan Africa, drives demand for effective diagnostic solutions. Regulatory frameworks are gradually improving, with support from organizations like the World Health Organization (WHO) to enhance tuberculosis control measures.

However, challenges such as limited healthcare infrastructure and funding persist, impacting market growth. Leading countries in this region include South Africa and Nigeria, where public health initiatives are being prioritized.

The competitive landscape is characterized by a mix of local and international players, with companies like BD and Cepheid working to provide innovative diagnostic solutions. Collaborative efforts between governments and NGOs are crucial in addressing the tuberculosis burden, paving the way for improved diagnostics and treatment options.

## Competitive Benchmarking

The Tuberculosis Diagnostics Market is currently characterized by a dynamic competitive landscape, driven by the increasing prevalence of tuberculosis (TB) and the urgent need for rapid and accurate diagnostic solutions. Key players such as Roche (CH), Abbott (US), and Thermo Fisher Scientific (US) are strategically positioned to leverage their technological advancements and extensive distribution networks. Roche (CH) focuses on innovation in molecular diagnostics, while Abbott (US) emphasizes the development of point-of-care testing solutions.
 
Thermo Fisher Scientific (US) is enhancing its portfolio through strategic partnerships and acquisitions, thereby shaping a competitive environment that prioritizes rapid response to market needs and technological integration. The market structure appears moderately fragmented, with several players vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their production to reduce costs and improve accessibility in emerging markets. This tactic not only enhances supply chain efficiency but also allows for tailored solutions that meet regional healthcare demands. The collective influence of these key players fosters a competitive atmosphere where innovation and operational efficiency are paramount. 
 
In August 2025, Roche (CH) announced the launch of a new molecular diagnostic test that significantly reduces the time required for TB detection. This strategic move is likely to enhance Roche's market position by addressing the critical need for timely diagnosis, which is essential for effective treatment and control of TB outbreaks. The introduction of this test aligns with global health initiatives aimed at eradicating TB, thereby reinforcing Roche's commitment to public health. 
 
In September 2025, Abbott (US) expanded its collaboration with local health authorities in India to enhance TB screening efforts through its rapid diagnostic tests. This partnership not only strengthens Abbott's foothold in a high-burden region but also demonstrates its commitment to addressing public health challenges. By localizing its efforts, Abbott is likely to improve access to diagnostics, which could lead to earlier detection and treatment of TB cases, ultimately contributing to better health outcomes. 
 
In July 2025, Thermo Fisher Scientific (US) acquired a biotechnology firm specializing in TB diagnostics, thereby expanding its capabilities in this critical area. This acquisition is indicative of Thermo Fisher's strategy to bolster its product offerings and enhance its competitive edge. By integrating innovative technologies from the acquired firm, Thermo Fisher is positioned to deliver more comprehensive solutions to healthcare providers, which may lead to improved diagnostic accuracy and efficiency. 
 
As of October 2025, the Tuberculosis Diagnostics Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in diagnostic processes. Strategic alliances among key players are increasingly shaping the competitive landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and respond swiftly to market demands.

## Recent News & Developments

The Tuberculosis Diagnostics Market is anticipated to reach a valuation of USD 2.5 billion by 2032, expanding at a CAGR of 5.16% from 2024 to 2032. The market growth is attributed to the increasing prevalence of tuberculosis, technological advancements in diagnostic techniques, and the rising demand for rapid and accurate diagnostic tests.

Key developments in the market include the approval of novel diagnostic tests, such as molecular assays and rapid diagnostic tests, which offer improved sensitivity and specificity. Additionally, the increasing focus on early detection and the growing awareness of tuberculosis control programs are expected to drive market expansion.

## Report Scope

| MARKET SIZE 2024 | 1.756(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.847(USD Billion) |
| MARKET SIZE 2035 | 3.055(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.16% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Abbott (US), Thermo Fisher Scientific (US), BD (US), Hologic (US), Cepheid (US), Mylan (IN), Siemens Healthineers (DE), Quotient Limited (GB) |
| Segments Covered | Disease Severity, Technology, Sample Type, Regional |
| Key Market Opportunities | Integration of artificial intelligence in Tuberculosis Diagnostics Market enhances accuracy and speed of disease detection. |
| Key Market Dynamics | Technological advancements in rapid testing methods are reshaping the Tuberculosis Diagnostics Market landscape. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Tuberculosis Diagnostics Market as of 2024?**
A: The Tuberculosis Diagnostics Market was valued at 1.756 USD Billion in 2024.

**Q: What is the projected market size for the Tuberculosis Diagnostics Market in 2035?**
A: The market is projected to reach 3.055 USD Billion by 2035.

**Q: What is the expected CAGR for the Tuberculosis Diagnostics Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during 2025 - 2035 is 5.16%.

**Q: Which companies are considered key players in the Tuberculosis Diagnostics Market?**
A: Key players include Roche, Abbott, Thermo Fisher Scientific, BD, Hologic, Cepheid, Mylan, Siemens Healthineers, and Quotient Limited.

**Q: How does disease severity impact the Tuberculosis Diagnostics Market valuation?**
A: In 2024, the market valuation for Low Severity was between 0.526 and 0.883 USD Billion, while Moderate Severity ranged from 0.703 to 1.174 USD Billion.

**Q: What are the different technology segments within the Tuberculosis Diagnostics Market?**
A: The market segments include Molecular Diagnostics, Microscopy-Based Diagnostics, Immunodiagnostics, and Culture-Based Diagnostics, with valuations ranging from 0.3 to 1.2 USD Billion.

**Q: What sample types are utilized in the Tuberculosis Diagnostics Market?**
A: Sample types include Sputum, Blood, Urine, and Tissue, with Sputum valued between 0.8 and 1.3 USD Billion in 2024.

**Q: What is the significance of molecular diagnostics in the Tuberculosis Diagnostics Market?**
A: Molecular Diagnostics is projected to have a valuation between 0.703 and 1.2 USD Billion, indicating its critical role in the market.

**Q: How does the Tuberculosis Diagnostics Market's growth compare across different sample types?**
A: Sputum diagnostics is expected to dominate, with a valuation range of 0.8 to 1.3 USD Billion, compared to Blood, Urine, and Tissue.

**Q: What trends are anticipated in the Tuberculosis Diagnostics Market by 2035?**
A: By 2035, the market is likely to expand significantly, driven by advancements in technology and increased focus on disease severity diagnostics.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/tuberculosis-diagnostics-market-11365*